Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Vikas Kapil , Ajay K Jain , Melvin D Lobo Added: 3 years ago
Up to one-in-five treated hypertensive patients are deemed to be treatment resistant1-3 (on at least three different anti-hypertensive medication classes, including a diuretic)4-6 and have high cardiovascular risk.7-9 There is a paucity of high-quality evidence to suggest that the addition of a fourth line (or fifth, sixth line, etc.) medication is likely to bring either hypertension under… View more
Author(s): Philipp Lurz , Karl Fengler Added: 3 years ago
The rise and fall of interventional renal sympathetic denervation (RDN) as a treatment for arterial hypertension is a remarkable chapter in the scientific history of the 21st century. This once promising therapy has been abandoned by most clinicians after the neutral results of the Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY-HTN3) trial.1 It would have been easy to… View more
Author(s): Lisa Brandon , Faisal Sharif Added: 3 years ago
Resistant hypertension remains a serious clinical burden despite significant advances in cardiology and healthcare. Hypertension is a chronic condition without any available cure, with significant associated morbidity and mortality, and necessitates lifelong use of medications. It is multifactorial in origin, associated with genetics, lifestyle factors and the metabolic syndrome. Resistant… View more
Author(s): Justin E Davies , Faisal Sharif , Oriol Rodriguez , et al Added: 3 years ago
Global Experts Discuss Renal Denervation as an Additional Treatment Option for Uncontrolled Hypertension Review the evidence on radiofrequency renal denervation, including safety, efficacy and durability dataand practical aspects around patient selection and management. Medical Education Program Patient Selection and Practical Implementation of Renal Denervation in Patients With… View more
Author(s): Joost Daemen , Added: 1 year ago
Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy. This page provides an overview of uRDN technology and the latest evidence from its associated RADIANCE clinical program. … View more
Author(s): Uwe Schwarzwälder , Thomas Zeller Added: 3 years ago
The first renal artery balloon angioplasties were performed by Felix Mahler in Berne and Andreas Grüntzig in Zurich in 1977 using self-made, bulky, coaxial balloon catheters.1,2 Until the beginning of the 1990s, balloon angioplasty was the only method of percutaneous treatment of renal artery stenosis (RAS) with satisfying acute and long-term results for angioplasty of stenoses caused by… View more
Author(s): William R Colyer Jr , Christopher J Cooper Added: 3 years ago
Renal artery stenosis (RAS) is a common manifestation of atherosclerotic disease. Although the exact prevalence rate for the population as a whole is unknown, RAS is seen in a significant proportion of patients who present with another manifestation of atherosclerosis (Table 1).1–7 Despite this high degree of prevalence, the management of RAS, specifically the role of revascularisation, remains… View more
Author(s): Andrew SP Sharp Added: 4 years ago
Prof Andrew Sharp (University Hospital of Wales, Cardiff, UK) discusses factors affecting lesion formation in RF renal denervation. Filmed on site at TCT 2019 in San Francisco by Radcliffe Cardiology. View more